Future Labs Live USA 2026 Signals the Next Battle for Competitive Advantage

Future Labs Live USA 2026 will take place Oct. 28-29, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Organized by Terrapinn, the event focuses on laboratory automation, AI, analytics, connectivity, sustainability, and operational efficiency across pharmaceuticals, biotechnology, healthcare, diagnostics, and laboratory technology. Confirmed speakers include leaders from Eli Lilly and Company, Novo Nordisk USA, Halozyme Therapeutics, Sanofi, Bristol Myers Squibb, Novartis, Roche, Genentech, and Adaptive Biotechnologies.

The speaker roster reflects a growing convergence between scientific discovery, research operations, laboratory automation, enterprise analytics, and digital infrastructure. The event arrives at a moment when laboratory modernization has become a board-level conversation across pharmaceutical, biotechnology, and research-intensive organizations, as pressure mounts to increase research productivity, improve data interoperability, accelerate automation initiatives, and modernize facilities without sacrificing compliance or quality.

Future Labs Live USA 2026 matters because it reflects a broader shift across life sciences and industrial research. Competitive advantage is increasingly being built inside the systems that support discovery, not just the discoveries themselves.

About Future Labs Live USA 2026

The technology industry loves visible outcomes. Investors celebrate approvals. Markets reward breakthroughs. Headlines focus on what emerges from the laboratory. The laboratory itself rarely gets equal attention, but that dynamic is beginning to change.

Future Labs Live USA 2026, organized by Terrapinn, sits at the center of a growing conversation around laboratory modernization. Terrapinn has built a global reputation for convening technology, healthcare, infrastructure, and innovation ecosystems, making Future Labs Live USA one of its most strategically relevant gatherings for the life sciences sector.

While much of the innovation economy remains focused on AI applications, drug development milestones, and scientific advances, laboratories are facing a different challenge. The infrastructure supporting discovery is being asked to evolve at the same pace as discovery itself. Data systems built for a previous generation of research are struggling under increasing complexity, automation programs are expanding beyond isolated workflows into enterprise-wide initiatives, and sustainability goals are moving from annual reports into operational requirements.

The result is a market increasingly focused on the mechanics of innovation.

Why This Matters

Scientific organizations have entered an era where execution is becoming a differentiator. The challenge is no longer a lack of ideas. The challenge is turning those ideas into repeatable, scalable outcomes.

A laboratory can possess world-class talent, promising research programs, and significant investment. If data remains fragmented, instruments fail to communicate effectively, or workflows remain heavily manual, productivity suffers. This reality is creating new demand for laboratory automation, laboratory analytics, instrument connectivity, enterprise data infrastructure, digital transformation, and operational excellence.

Future Labs Live USA 2026 brings those conversations together under one roof in Philadelphia. More importantly, it brings together the people responsible for making those systems work.

The Operators Behind Laboratory Transformation

The early speaker lineup provides a useful snapshot of where laboratory modernization is heading. Carleen Klumpp-Thomas, Senior Director of Lab Automation Engineering at Eli Lilly and Company, represents one of the industry's most active areas of investment: scaling automation across complex research environments. Saritha Kuriakose, VP at Novo Nordisk USA, joins a broader group of pharmaceutical leaders focused on operational performance and organizational transformation.

Angela Hui, VP of Operations at Halozyme Inc., Brandon King, Director of Site Operations at Sanofi, and Peter Chase, Scientific Director of Core Automation at Bristol Myers Squibb bring perspectives from organizations managing large-scale scientific operations. The data, connectivity, and analytics side of the equation is equally represented by Ferhat Yilmaz, Director of Enterprise & Pipeline Insights & Analytics at Novartis, and Billy Jun, Global Product Manager for Lab Instrument Connectivity at Roche.

The lineup is rounded out by Anubhav Srivastava of Novo Nordisk Inc., Wan-Chih Su of Genentech, and Yousef Baioumy of Adaptive Biotechnologies. Different companies and different mandates often lead back to a remarkably similar set of operational questions.

Market Context: Laboratories Are Becoming Strategic Infrastructure

For years, technology conversations centered on software platforms. Then cloud infrastructure became strategic. Then cybersecurity became strategic. Now laboratories are moving into that same category as research-driven organizations increasingly view laboratory operations as a source of competitive advantage rather than simply a cost center.

That shift is reshaping investment priorities. Automation is no longer a future initiative. Connectivity is no longer optional. Data quality is no longer an IT problem. Sustainability is no longer a separate conversation. These priorities are becoming interconnected.

Organizations that successfully align automation, analytics, facilities, sustainability, and operational execution are often able to accelerate research timelines while improving consistency and scalability. Organizations that fail to connect those pieces face growing friction, and the gap between those two groups is becoming increasingly visible.

Why Philadelphia Matters Right Now

Philadelphia has long occupied an important position within the life sciences ecosystem. Hosting Future Labs Live USA 2026 at the Pennsylvania Convention Center places the event inside one of the country's most significant healthcare, biotechnology, and research corridors.

That geographic context matters because the event is not simply gathering technology vendors and industry observers. It is bringing together leaders operating inside the environments where laboratory modernization decisions are made every day.

For founders building laboratory technology, investors evaluating scientific infrastructure, and operators responsible for transformation initiatives, that concentration of expertise creates unusually valuable signal density. The best industry events don't just reflect markets. They reveal where markets are heading.

What This Signals for Pharma, Biotech, and Enterprise Technology

A common misconception persists across innovation ecosystems. Many assume the next decade of scientific progress will be determined primarily by breakthrough discoveries. The reality may be less dramatic and far more operational.

The organizations creating outsized outcomes are increasingly the ones improving the systems behind discovery through better data, better automation, better interoperability, and better operational design. Those improvements rarely generate headlines, but they frequently generate results.

Future Labs Live USA 2026 reflects that shift. The event's significance extends beyond laboratories themselves. It represents a broader recognition that scientific infrastructure, research operations, laboratory automation, and execution are becoming central drivers of innovation performance. The future of discovery may depend as much on workflow architecture as scientific inspiration, and that is the conversation heading to Philadelphia.